Signal transduction pathway targets for anticancer drug discovery

Research output: Contribution to journalReview article

33 Citations (Scopus)

Abstract

There are currently over 80 agents officially approved for the treatment of cancer world-wide. However, the most common epithelial cancers, which cause greater than 75% of cancer deaths, remain incurable. Most drugs have been developed empirically by testing large numbers of chemicals on rapidly growing transplantable rodent tumors, and more recently, human tumor xenografts. This approach has identified prodeminantly DNA-active drugs that are considerably toxic and have limited efficacy. Novel molecular targets, which are selective for neoplastic cells, are needed for chemotherapeutic agents to improve cure rates of epithelial malignancies, with acceptable toxicity. In recent years, agents inhibiting signal transduction pathway molecules have entered clinical trials. These include antibodies and small molecules, which inhibit growth factor receptors and their receptor tyrosine kinases, inhibitors of cytoplasmic second messengers such as ras, raf and MEK, inhibitors of protein trafficking, and inhibitors of protein degradation.

Original languageEnglish (US)
Pages (from-to)361-378
Number of pages18
JournalCurrent Pharmaceutical Design
Volume6
Issue number4
DOIs
StatePublished - Jan 1 2000

Fingerprint

Drug Discovery
Signal Transduction
Neoplasms
Growth Factor Receptors
Poisons
Mitogen-Activated Protein Kinase Kinases
Receptor Protein-Tyrosine Kinases
Second Messenger Systems
Protein Transport
Heterografts
Pharmaceutical Preparations
Proteolysis
Rodentia
Clinical Trials
Antibodies
DNA

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Signal transduction pathway targets for anticancer drug discovery. / Adjei, Alex.

In: Current Pharmaceutical Design, Vol. 6, No. 4, 01.01.2000, p. 361-378.

Research output: Contribution to journalReview article

@article{d6a74122fc154dafae7a0e08a788197a,
title = "Signal transduction pathway targets for anticancer drug discovery",
abstract = "There are currently over 80 agents officially approved for the treatment of cancer world-wide. However, the most common epithelial cancers, which cause greater than 75{\%} of cancer deaths, remain incurable. Most drugs have been developed empirically by testing large numbers of chemicals on rapidly growing transplantable rodent tumors, and more recently, human tumor xenografts. This approach has identified prodeminantly DNA-active drugs that are considerably toxic and have limited efficacy. Novel molecular targets, which are selective for neoplastic cells, are needed for chemotherapeutic agents to improve cure rates of epithelial malignancies, with acceptable toxicity. In recent years, agents inhibiting signal transduction pathway molecules have entered clinical trials. These include antibodies and small molecules, which inhibit growth factor receptors and their receptor tyrosine kinases, inhibitors of cytoplasmic second messengers such as ras, raf and MEK, inhibitors of protein trafficking, and inhibitors of protein degradation.",
author = "Alex Adjei",
year = "2000",
month = "1",
day = "1",
doi = "10.2174/1381612003400821",
language = "English (US)",
volume = "6",
pages = "361--378",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Signal transduction pathway targets for anticancer drug discovery

AU - Adjei, Alex

PY - 2000/1/1

Y1 - 2000/1/1

N2 - There are currently over 80 agents officially approved for the treatment of cancer world-wide. However, the most common epithelial cancers, which cause greater than 75% of cancer deaths, remain incurable. Most drugs have been developed empirically by testing large numbers of chemicals on rapidly growing transplantable rodent tumors, and more recently, human tumor xenografts. This approach has identified prodeminantly DNA-active drugs that are considerably toxic and have limited efficacy. Novel molecular targets, which are selective for neoplastic cells, are needed for chemotherapeutic agents to improve cure rates of epithelial malignancies, with acceptable toxicity. In recent years, agents inhibiting signal transduction pathway molecules have entered clinical trials. These include antibodies and small molecules, which inhibit growth factor receptors and their receptor tyrosine kinases, inhibitors of cytoplasmic second messengers such as ras, raf and MEK, inhibitors of protein trafficking, and inhibitors of protein degradation.

AB - There are currently over 80 agents officially approved for the treatment of cancer world-wide. However, the most common epithelial cancers, which cause greater than 75% of cancer deaths, remain incurable. Most drugs have been developed empirically by testing large numbers of chemicals on rapidly growing transplantable rodent tumors, and more recently, human tumor xenografts. This approach has identified prodeminantly DNA-active drugs that are considerably toxic and have limited efficacy. Novel molecular targets, which are selective for neoplastic cells, are needed for chemotherapeutic agents to improve cure rates of epithelial malignancies, with acceptable toxicity. In recent years, agents inhibiting signal transduction pathway molecules have entered clinical trials. These include antibodies and small molecules, which inhibit growth factor receptors and their receptor tyrosine kinases, inhibitors of cytoplasmic second messengers such as ras, raf and MEK, inhibitors of protein trafficking, and inhibitors of protein degradation.

UR - http://www.scopus.com/inward/record.url?scp=0034080399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034080399&partnerID=8YFLogxK

U2 - 10.2174/1381612003400821

DO - 10.2174/1381612003400821

M3 - Review article

C2 - 10788587

AN - SCOPUS:0034080399

VL - 6

SP - 361

EP - 378

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 4

ER -